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ABSTRACT: The factor H binding protein (fHbp) is a key virulence factor of
Neisseria meningitidis that confers to the bacterium the ability to resist killing by
human serum. The determination of its three-dimensional structure revealed that
the carboxyl terminus of the protein folds into an eight-stranded β barrel. The
structural similarity of this part of the protein to lipocalins provided the rationale
for exploring the ability of fHbp to bind siderophores. We found that fHbp was
able to bind in vitro siderophores belonging to the cathecolate family and mapped
the interaction site by nuclear magnetic resonance. Our results indicated that the
enterobactin binding site was distinct from the site involved in binding to human
factor H and stimulates new hypotheses about possible multiple activities of fHbp.
Neisseria meningitidis is an obligate human pathogen that can
cause severe and sometimes fatal septicaemia and meningi-
tis.1−3 Meningococcal serogroup B has long been identified as
an important cause of disease in many parts of the world.
However, vaccine development has been hindered by the
biochemistry of its capsular polysaccharide4−6 and the
difficulties inherent in identifying appropriate surface protein
antigens.7 The use of reverse vaccinology to select antigens
suitable for vaccine development led to identification of a
number of novel proteins.8 As a result a multicomponent
vaccine has been proposed,9 which includes among the other
antigens fHbp, a surface-anchored lipoprotein previously
termed genome-derived neisserial antigen 1870 (GNA1870),8
or LP20286.10 fHbp is able to induce a strong immune
response in animals and humans.11−13
fHbp is prone to sequence variability, so that three distinct
variants of the protein can be recognized in the meningococcal
population.14 Each variant is, however, able to bind human
factor H (fH), a negative regulator of the alternative
complement pathway.15 fH is a 150 kDa polypeptide composed
of 20 domains of ∼60 amino acid each16 called short consensus
repeats (SCRs) arranged in a consecutive fashion. fH is
normally present at high concentrations in human serum.17 Its
binding to the surface of human cells protects them from
autoimmune attack.17,18 Meningococci evolved the ability to
capture human fH on their surface thanks to the direct
interaction with fHbp. It has been shown that fH binds fHbp
via SCR6 and -7.19 Such interaction allows the meningococcus
to evade the innate immunity of the host.20
The three-dimensional structure of fHbp, free21−23 or in
complex with SCR6 and -7 of human factor H,19 showed that
the meningococcal protein consists of two domains connected
by a flexible linker. While the N-terminal domain adopts an
elongated “barrel-like” structure characterized by the presence
of long loops and by extensive flexibility, the C-terminal portion
of the molecule is arranged in a well-defined β barrel that is
stabilized by a regular network of hydrogen bonds. The
structure of the C-terminal domain shows a remarkable
similarity to those of lipocalins.24 Lipocalins form a wide
family of proteins expressed by plants, fungi, bacteria,
vertebrates, and invertebrates25,26 that participate in many
biological functions, including binding to siderophores. With
the name siderophores are collectively indicated a variety of
organic chelators that have a strong affinity for ferric iron. This
metal is essential for the growth and development of almost all
living organisms, including bacteria that during infection cannot
freely access the host iron reservoir, as the metal is tightly
sequestered by proteins or hemes in the host. Because of this
competition between pathogenic bacteria and the human host
for ferric iron uptake, siderophores are considered to be
virulence factors because of their capacity to feed micro-
organisms with this metal.27
The structural similarity of fHbp to lipocalins prompted us to
investigate the possible role of fHbp as a siderophore-binding
protein. In this work, we initially explored the affinity of
recombinant meningococcal fHbp for different siderophores in
vitro. Our results show that the protein is able to bind
enterobactin, a feature that is shared with its orthologue in
Neisseria gonorrheae. These observations suggest that fHbp
could be involved in iron uptake and for this reason play an
important role in bacterial survival in the human body.
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■ MATERIALS AND METHODS
fHbp Expression and Purification. The f Hbp alleles were
amplified by polymerase chain reaction from the chromosomal
DNA of N. meningitidis strains MC58, 2996, and M1239, while
the chromosomal DNA of N. gonorrheae strain FA1090 was
used to amplify the gonococcal gene. All the alleles were cloned
into the pET21b vector (Novagen) under the control of the T7
promoter. Recombinant fHbp was expressed in the Escherichia
coli BL21(DE3) strain as a C-terminal histidine fusion. Protein
expression was induced by isopropyl 1-thio-β-D-galactopyrano-
side (IPTG) (Sigma), and then fHbp was purified by nickel
chelating affinity chromatography using a HisTrap HP column
(GE Healthcare) followed by cationic exchange chromatog-
raphy. The purified protein was dialyzed in PBS buffer. For
NMR analysis, the BL21(DE3) E. coli clone was grown in
ISOGRO 15N (Sigma). After protein purification, the final
product was dialyzed in 20 mM sodium phosphate (pH 7.2), a
specific requirement for NMR. Unlabeled variant 1 fHbp was
purified following the same procedure, while fHbp variants 2
and 3 and the gonococcal isoform were purified by nickel
chelating affinity chromatography and then anionic exchange
chromatography and finally dialyzed in phosphate-buffered
saline (PBS).
Native Gel Electrophoresis. Samples containing 100 μg of
purified full-length fHbp-his were mixed and incubated for 1 or
8 h at room temperature, at a 1:1 molar ratio with commercially
available ferric enterobactin [FeIII(Ent)3−], ferric salmochelin,
ferric yersiniabactin [FeIII(Yers)], and ferric aerobactin
[FeIII(Aer)], all acquired from EMC microcollections GmbH,
in PBS. Then the samples were mixed with Tris-glycine native
sample buffer and loaded on Novex Tris-glycine or Novex Tris-
acetate native gels (Invitrogen). Gels were run at 150 V
constantly for 2 h and stained with SimplyBlue Safe Stain
(Invitrogen).
Surface Plasmon Resonance (SPR) Analysis. All SPR
experiments were performed using a Biacore T100 instrument
(GE Healthcare) equilibrated at 25 °C. fHbp proteins were
immobilized on the sensor surface as ligands, and siderophores
were injected as analytes in optimized running buffer that
consisted of PBS (pH 7.4), 0.05% P-20 detergent, and 2%
methanol. For each titration, fHbp proteins were first covalently
immobilized by amine coupling on a carboxymethylated
dextran sensor chip (CM-5, GE Healthcare). Amine coupling
reactions for immobilization of fHbp were performed using
purified proteins at ∼10 μg/mL in 10 mM sodium acetate
buffer (pH 5.5) injected at a rate of 5 μL/min until ∼2000
response units (RU) were captured. The blank (reference)
surface was constructed similarly, although without fHbp.
A buffer optimization was necessary to run titration
experiments because a growing nonlinear analyte response
was observed upon binding, and the resulting sensorgrams
could not be fit with any standard evaluation method. Preparing
the initial analyte stock in a 100% methanol solution and then
diluting the stock to a final methanol concentration of 2% in
running buffer resolved this issue (PBS and 0.05% P-20).
Titration experiments were performed by injecting
FeIII(Ent)3− prepared at increasing concentrations in optimized
running buffer at a flow rate of 50 μL/min. Following each
injection, sensor chip surfaces were regenerated with a 30 s
injection of 10 mM NaOH. Each titration series contained 10−
12 analyte injections, with maximal used siderophore
concentrations of 280 μM. Data were analyzed using Biacore
T100 Evaluation (GE Healthcare); a blank injection of buffer
only was subtracted from each curve, and reference sensor-
grams were subtracted from experimental sensorgrams to yield
curves representing specific binding. Steady-state analysis was
used to plot the equilibrium binding response (Req) against
analyte concentration to obtain the dissociation constants (KD)
(see the Supporting Information for details).
Ferric yersiniabactin, ferric aerobactin, and iron free
enterobactin were tested as a single injection at 100 μM over
immobilized proteins, and binding with FeIII(Ent)3− at the same
concentration was used for comparison. Similarly, fH (domains
6 and 7) was injected at a concentration of 100 nM over
immobilized gonococcal fHbp and compared for binding with a
100 μM FeIII(Ent)3− injection.
NMR Interaction Studies. The interaction of FeIII(Ent)3−,
iron free enterobactin (apo-Ent), and ferric FeIII(Yers)3− with
15N-labeled fHbp was investigated by NMR spectroscopy
performed at 298 K on Bruker Avance 900 and 800 MHz
spectrometers, at proton nominal frequencies of 899.20 and
800.13 MHz, respectively, using triple-resonance (TXI 5 mm)
cryoprobes equipped with pulsed-field gradients along the z-
axis.
All titrations were performed with 0.5 mM 15N-labeled fHbp
protein samples by adding siderophores up to an fHbp:sider-
ophore molar ratio of 1:5. 1H and 15N resonance assignments
for the fHbp protein were available.23 All samples were in 20
mM phosphate buffer (90% H2O and 10% D2O) at pH 7.2. All
two-dimensional spectra were processed using TOPSPIN
(Bruker BioSpin).
The information obtained from the NMR interaction studies
between fHbp and FeIII(Ent)3− was used as input for generating
a model of the adduct through molecular docking. Docking
calculations between fHbp and FeIII(Ent)3− were performed
with HADDOCK2.0.28 Twenty conformers of the fHbp
solution structure (PDB entry 2KC0) and the PDB coordinates
of the siderophores extracted from the crystal structure on the
human siderocalin NGAL complexed with FeIII(Ent)3− (PDB
entry 3CMP) were used as input. The topologies and
parameter files for FeIII(Ent)3−, necessary to run HAD-
DOCK2.0, were generated by PRODRG (http://davapc1.
bioch.dundee.ac.uk/prodrg/)29 using the PDB coordinates
extracted from the 3CMP crystal structure. The docking
calculations in HADDOCK were driven by nine active and nine
passive residues (Table S1 of the Supporting Information),
which were used to generate ambiguous interaction restraints,
as defined in the HADDOCK protocol.9,30 The active residues
are those experimentally identified to be involved in the
interaction between fHbp and FeIII(Ent)3− and solvent-
accessible, i.e., solvent-exposed residues whose line widths of
the NH signals increase upon addition of paramagnetic
FeIII(Ent)3−. The passive residues are all solvent-accessible
surface neighbors of active residues. The solvent accessibility of
fHbp was calculated with NACCESS.31 Flexible regions of the
proteins were defined on the basis of active and passive residues
and two preceding and following residues. Additional distance
restraints with an upper bound distance of 2.0 Å were defined
between the FeIII atom and the six catechol oxygens according
to previously reported protocols.32−35
During the initial rigid-body docking calculation, the
intermolecular interactions have been scaled down to a value
of 0.01. In this phase, 1000 structures of the complex were
generated and the best 200 in terms of total intermolecular
energy were further submitted to semiflexible simulated
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annealing and final refinement in water. The initial temperature
for the second torsion angle dynamic (TAD) cooling step with
a flexible side chain at the interface was set up to 500 K. The
molecular dynamics trajectory steps for rigid body high-
temperature TAD and during the first rigid body cooling
stage were set up to zero, while the numbers of MD steps
during the second and third cooling stages with flexible side
chains at the interface were set up to 500. The final 200
structures were then clustered using a cutoff of 2.0 Å of the
root-mean-square deviation (rmsd) among any structure of a
cluster. The docking solution could be divided into two
clusters, which were ranked on the basis of the average
HADDOCK score. Table S2 of the Supporting Information
reports the statistics calculated over the best four models of
each cluster.
■ RESULTS
fHbp−Enterobactin Interaction Revealed by Native
Polyacrylamide Gel Electrophoresis (PAGE). On the basis
of their chemical structure (Figure 1), siderophores can be
subdivided into catecholates, hydoxamates, or mixed classes.
Cathecolates (enterobactin and salmochelin), a hydroxamate
(aerobactin), and a mixed siderophore (yersiniabactin) were
selected as representative members of the respective classes and
tested for their ability to bind to recombinant meningococcal
fHbp by native gel electrophoresis.
A faster gel migration was detected for fHbp after incubation
in the presence of enterobactin and, to a lesser extent, after
incubation with salmochelin (Figure 2). On the other hand,
preincubation of fHbp with aerobactin and yersiniabactin did
not alter its electophoretic pattern. The faster migration of the
fHbp−FeIII(Ent)3− complex was likely due to an altered
electrostatic potential on the fHbp surface when it was bound
to enterobactin. We concluded therefore that fHbp was able to
bind catecholates in vitro and that such interaction was more
pronounced in the case of enterobactin.
SPR Binding Studies. To confirm the indications derived
from native PAGE, we analyzed the binding affinity of
Fe(Ent)3− for immobilized fHbp by surface plasmon resonance
Figure 1. Prototypical members of the main siderophore classes. (a) Chelating groups are represented by three cathecolate units. (b) Ligating groups
include the oxygen atoms of hydroxamate. (c) Siderophores with mixed ligands and heterocyclic chelating groups.
Figure 2. Native PAGE of 10 μg of fHbp alone (lane 1) and fHbp in
the presence of different ferric siderophores at a 1:1 molar ratio:
FeIII(Ent)3− (lane 2), FeIII(Sal)3− (lane 3), FeIII(Yers) (lane 4), and
FeIII(Aer) (lane 5).
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(SPR). FeIII(Yers) and FeIII(Aer) were also included in the
analysis as negative controls.
SPR profiles clearly demonstrated binding of fHbp to
FeIII(Ent)3−, while no interaction was observed with FeIII(Yers)
and FeIII(Aer) (Figure 3A). The fHpb affinity was specific for
the FeIII(Ent)3− form, as no interaction was observed with the
apo-Ent form (Figure 3B). Of interest, the affinity for
FeIII(Ent)3− appeared to be maintained by the gonococcal
orthologue of fHbp, which did not show any binding to
domains 6 and 7 of fH (Figure 3C).
Titrations with increasing concentrations of FeIII(Ent)3−
(ranging from 2.2 to 240 μM) were performed on immobilized
fHbp from the meningococcal MC58 strain (variant 1). The
shape of the curves prevented fitting the sensorgrams with any
Biacore T100 Evaluation kinetic models. However, steady-state
analysis of the curves provided an estimated value for the
thermodynamic dissociation constant (KD) of 35 μM for
binding of FeIII(Ent)3− to fHbp (Figure 4). Results for fHbp
variants 2 and 3, tested using fHbp from strains 2996 and
M1239, respectively, showed comparable affinities and similar
profiles of association and dissociation behavior (Table S3 of
the Supporting Information).
NMR Mapping of the fHbp−Enterobactin Interaction.
The interaction between FeIII(Ent)3− and fHbp was further
characterized by NMR by analyzing the chemical shift
perturbations in the 1H−15N HSQC spectrum of the protein
caused by the addition of apo-Ent and FeIII(Ent)3−. Analysis of
the interaction with FeIII(Yers) was also included as a negative
control.
Addition of increasing amounts of paramagnetic FeIII(Ent)3−
to 15N-labeled fHbp resulted in a progressive increase in the
line widths of Gly148, Arg149, Ala150, Thr151, Arg153,
Lys230, Gln232, Lys254, and Gln255 NH cross-peaks in the
1H−15N HSQC spectra. Such signals disappeared at an
fHbp:FeIII(Ent)3− molar ratio of 1:5 (Figure S1 of the
Supporting Information). The FeIII bound to enterobactin is
highly paramagnetic, being in a high-spin S = 5/2 state. This
added a large contribution to the nuclear relaxation rates, thus
increasing signal line widths beyond detection.
The binding to fHbp was very specific for FeIII(Ent)3− as no
effects were detected on the NMR spectra when apo-Ent was
added to the sample (Figure S2 of the Supporting
Information). No perturbations were detected in the NMR
spectra when a solution of FeCl3 was added, indicating that Fe
III
ions alone were not directly coordinated by the protein.
The same spectral changes observed upon addition of
FeIII(Ent)3− were restored either when a solution of FeCl3 was
added to an fHbp/apo-Ent mixture or when apo-Ent was added
to an fHbp/FeIII mixture (Figure S2 of the Supporting
Information). Indeed, apo-Ent readily formed a complex with
FeIII, generating FeIII(Ent)3−, which was the only form able to
bind to fHbp.
The specificity of FeIII(Ent)3− for fHbp was confirmed by the
absence of interactions of fHbp with other siderophores such as
FeIII(Yers)3−. In line with the absence of binding observed
through SPR analysis, no changes were observed in the 1H−15N
HSQC fHbp spectrum upon addition of FeIII(Yers) (Figure S3
of the Supporting Information).
The protein residues involved in the protein−small molecule
interaction were mapped onto the NMR structure (PDB entry
2KC0). All residues, whose NH cross-peak disappeared upon
addition of FeIII(Ent)3−, were located on the C-terminal
domain (Figure 5). A multiple alignment of the different
Figure 3. Solution-phase FeIII(Ent)3−−fHbp binding measured by
surface plasmon resonance. (A) Representative sensorgrams show the
response over time [resonance units (RU)] during the binding at
neutral pH of FeIII(Ent)3− to immobilized recombinant fHbp from
strain MC58. FeIII(Yers)3− and FeIII(Aer) are not able to bind fHbp.
(B) Binding to enterobactin is specific for FeIII(Ent)3− as no
interaction is observed with the apo-Ent form. (C) Binding properties
of the the N. gonorrheae fHbp allele. The protein is able to bind to
FeIII(Ent)3− (red) but does not have affinity for domains 6 and 7 of
human factor H (green), which contain the interaction site with the
meningococcal allele.20
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fHbp variants showed that such amino acids were generally well
conserved or carried conservative substitutions, enforcing the
hypothesis that they could form a functional site of the protein
surface (Figure 6).
The 200 docking solutions of models of the fHbp−
FeIII(Ent)3− adduct could be divided into two clusters. In
each case, FeIII(Ent)3− interacted with the same region of the
protein, and the location of enterobactin in the two clusters was
comparable, with only minor differences in the conformations
of the three catecholate rings (Figure S4 of the Supporting
Information). From the analysis of the energetic and scoring
functions, both clusters had similar energy term values,
numbers of violations, and buried surface areas, although
cluster 1 showed a slightly lower HADDOCK score (Table S2
of the Supporting Information). The average structure of this
cluster is shown in Figure 7. fHbp binds FeIII(Ent)3− in a
solvent-exposed area of its surface, arranging the side chain of
two positively charged residues (Lys230 and Arg149) between
two of the three catecholate rings of FeIII(Ent)3−. Additional
stabilizing hydrophobic contacts were made by residues lining
the interaction site, such as Tyr152, Phe172, and Ala231 and
FeIII(Ent)3−. Hydrogen bonds between the carbonyl oxygen of
the amide connecting the cathecolate to the backbone of
enterobactin molecule and both the side chain and the amide
group of the Thr151 were found in all the docking solutions
(Figure S5 of the Supporting Information).
■ DISCUSSION
Bacterial pathogens require iron for growth; however, in their
host, the level of free iron is tightly regulated and is not readily
available. For this reason, microbes have evolved a number of
iron uptake systems to ensure access to the level of iron that is
required for their survival. For example, N. gonorrheae and N.
meningitidis can sequester iron from hemoglobin by means of
major iron-regulated proteins.36,37 Other bacteria, including E.
coli, Salmonella, Yersinia, Bacillus, Vibrio, and Mycobacterium
spp., secrete siderophores, which are high-affinity compounds
that chelate ferric iron from the environment. In other cases,
bacteria can use siderophores produced by other micro-
organisms (xenosiderophores). N. meningitidis expresses a
number of surface receptors for host iron-containing proteins,
including transferrin and lactoferrin.37,38 Additionally, although
its ability to produce siderophores has not been demonstrated,
the meningococcus expresses the outer membrane siderophore
receptor FrpB, whose orthologue in N. gonorrheae, named FetA,
has been characterized as a TonB-dependent receptor capable
of binding a range of catecholate siderophores, including
enterobactin,39 salmochelin, and dihydroxybenzoylserine.40
This raised the question of whether the meningococcus can
actually take up iron through xenosiderophores and motivated
our search for possible novel siderophore receptors.
The structural similarity of the fHbp C-terminal domain to
lipocalins suggested that fHbp could play the role of a
siderophore receptor. As siderophores have extremely hetero-
geneous structures, we probed the hypothesis by examining the
affinity of fHbp for four molecules identified as being
representative of the main chemical classes. i.e., catecholates,
hydroxamates, and mixed. In particular, we focused the choice
on two cathecolates (enterobactin and salmochelin), the
hydroxamate aerobactin and the mixed-type yersiniabactin, all
of them known to be produced by pathogenic bacteria.27 We
found that fHbp was able to bind in vitro FeIII(Ent)3−, a
xenosiderophore produced by E. coli and Salmonella spp.41
NMR mapping revealed that the site of binding interaction with
enterobactin was clearly distinct from the zone of the fHbp
surface that is known to interact with factor H. Docking
calculations performed with HADDOCK suggest that the ferric
Figure 4. SPR analysis of the fHbp−siderophore interactions. (A)
FeIII(Ent)3− was injected over immobilized fHbp from the MC58
strain. The SPR curves demonstrated a clear dose−response
relationship. The titration included FeIII(Ent)3− concentrations from
2.2 to 280 μM. (B) Steady-state binding analysis of the sensorgrams
from panel A allowed determination of the equilibrium binding
constant (KD) of 35 μM for the Fe
III(Ent)3−−fHbp interaction. The
vertical solid line indicates the concentration of the calculated KD
value.
Figure 5. fHbp−enterobactin interaction site identified by NMR.
Surface-accessible residues (Gly148, Arg149, Ala150, Thr151, Arg153,
Lys230, Gln232, Lys254, and Gln255) whose amide signals were
perturbed upon the addition of FeIII(Ent)3− (see the text for details)
are represented as balls and sticks. This figure was prepared with
UCSF Chimera (http://www.cgl.ucsf.edu/chimera/).
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siderophore rests at the surface of one extremity of the C-
terminal β barrel.
The HADDOCK model of the fHbp−FeIII(Ent)3− adduct
showed several analogies to the already characterized
complexes of enterobactin with NGAL and Q83 lipocalins.42,43
Both NGAL and Q83 display a highly conserved structural fold
constituted by an eight-stranded antiparallel β barrel, which
encloses a cup-shaped FeIII(Ent)3− binding site. However,
FeIII(Ent)3− interacted less deeply in the β barrel of fHbp where
the binding site is more shallow. As a consequence, in the
fHbp−FeIII(Ent)3− adduct, one of the catecholate rings did not
have any contact with the protein and was completely exposed
to the solvent (Figure S5 of the Supporting Information). This
represented a major difference versus what has been observed
in NGAL− and Q83−FeIII(Ent)3− adducts, in which the three
catecholate rings are deeply buried within the positively
charged pocket. The differences in binding could reflect the
different affinity observed between the fHbp−FeIII(Ent)3−
adduct and the other two lipocalin−enterobactin complexes,
whose KD values were both estimated to be in the nanomolar
range.42,43
All of the three fHbp variants analyzed bind FeIII(Ent)3− with
similar affinities (Table S3 of the Supporting Information). The
fHbp residues identified in the model as interacting with
FeIII(Ent)3− via their side chains (Figure S5 of the Supporting
Information) were well conserved among the fHbp variants or
subjected to conservative substitutions (Figure 6). In particular,
Gln232 and Gln255, both invariant in the sequence alignment,
established polar interactions with enterobactin O11 and O13
atoms, respectively. The side chains of Arg230 and Arg149
were arranged between the catecholate rings of FeIII(Ent)3−,
indicating that positively charged amino acids within fHbp
Figure 6. Multiple-sequence alignment of different fHbp variants. Meningococcal alleles previously identified as being representative of the natural
variability (15) are labeled from 1.1 to 3.28 in accordance with the nomenclature adopted in the public fHbp database (http://www.neisseria.org).
Gonococcal sequences were retrieved from the complete genome sequences of strains FA1090 (entry YP_207214), F62 (entry ZP_06641974), and
DGI18 (entry ZP_04720259) filed in the protein section of the National Center for Biotechnology Information public database (http://www.ncbi.
nlm.nih.gov/protein). Residues forming the enterobactin binding site are marked by red circles. Putative signal peptides are evidenced with green
bars.
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recognize the catechol groups of FeIII(Ent)3− by interacting
with their aromatic electron density and forming cation−π
bonds. Moreover, in a manner different from that of neutral
apo-Ent, the formation of the tris-catecholate coordination
structure in FeIII(Ent)3− can maximize cationic−π and
Coulombic interactions within the fHbp binding site. The
majority of fHbp subvariants have positively charged residues
(arginine or lysine) at position 230 and 149 (Figure 6).
However, the observation that in a few cases (fHbp alleles 1.14
and 1.10) nonconservative substitutions can occur suggests that
the network of interactions stabilizing the enterobactin could be
different in some alleles or, as an alternative, that such alleles
might have a different affinity for enterobactin.
Additional stabilizing hydrophobic contacts were made by
residues lining the interaction site, such as Tyr152 and Phe172,
both of which are strictly conserved within the three variants
(Figure 6). The line widths of the amide signal of Tyr152 in
particular increased upon addition of paramagnetic FeIII(Ent)3−.
Overall, the model suggests that both the charge and the
structure of FeIII(Ent)3− are responsible for fHbp recognition,
and this could explain why FeIII(Yers) and FeIII(Aer), both
lacking catecholate rings, do not bind fHbp because of the
neutral nature of their ferric complexes and the lack of aromatic
binding units.
The use of E. coli siderophores in N. gonorrheae has been well
documented.40 It was not therefore unforeseen that the
gonococcal fHbp homologue was also able to bind enter-
obactin. The ability of meningococcal fHbp to bind enter-
obactin was instead somewhat surprising, considering that the
niches colonized by the meningococcus render it improbable
that it has evolved to exploit siderophores in vivo that are
produced by Enterobacteria.
It has already been pointed out that the gonococcal fHbp
differs at the N-terminus compared to meningococcal variants,
and it has been speculated that the gonococcal polypeptide,
which lacks a signal peptidase II motif, remains confined in the
cytoplasm.44 However, sequence inspection suggests that
gonococcal fHbp can be recognized by a twin-arginine
translocation system,45 which could direct it to the periplasmic
space (Figure 6). This observation leads to the intriguing
hypothesis that the same protein differentiated its activity and
function in N. meningitidis and N. gonorrheae, by modulating its
subcellular localization and affinity for different substrates. In
the gonococcus, the protein could be located in the periplasm
where it could exert a role in iron uptake, whereas the surface-
located orthologue in N. meningitidis mediates fH binding to
allow escape of the host immune system. On the other hand,
SPR indicated that the recombinant gonococcal fHbp allele is
unable to bind to fH. This raises the question of whether fHbp
is an appropriate name for the gonococcal orthologue and
suggests that molecule transport could represent its predom-
inant role.
Such considerations cannot, however, lead us to exclude the
possibility that the maintenance of the ability to bind
siderophores represents an advantage also for the meningo-
coccus. The presence in the meningococcal genome of a gene
encoding FrpB, the orthologue of the gonococcal enterobactin
receptor FetA, seems to suggest that the maintenance of
potential receptors for iron scavenging could provide a useful
reservoir that allows the bacterium to rapidly adapt to possible
environmental changes.
The biological significance of binding of fHbp to FeIII(Ent)3−
in meningococcus remains to be investigated. The low affinity
of this complex suggests that fHbp could represent the
primitive function of fHbp on which fH binding successively
Figure 7. Lowest-score structural model of the fHbp−FeIII(Ent)3− complex. The FeIII(Ent)3− molecule is shown as sticks (green for carbon, blue for
nitrogen, red for oxygen, and an orange sphere for the Fe atom). The surface of the protein is colored dark green. Residues involved in the
interaction with human fH are mapped in yellow onto the protein surface. (A) Electrostatic potential surface of fHbp. (B) The FeIII(Ent)3− molecule
is also shown. Key residues involved in electrostatic and cation−π interactions with FeIII(Ent)3− are labeled on the protein electrostatic surface.
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prevailed to enhance the fitness of the bacterium in human
blood.
As an alternative, fHbp could physiologically bind a different
currently unknown siderophore or a modification product of
ferric enterobactin. It has been recently demonstrated that in
response to colonization by both Gram-positive and Gram-
negative pathogens the mammalian nasal mucosa reacts by
secreting lipocalin_2 (Lpn2), a potent iron scavenger of apo
and ferric enterobactin.46,47 Lpn2 acts as a bacteriostatic agent,
silencing one of the most effective ways to acquire iron within
the host and providing a natural barrier that bacteria have to
overcome to successfully colonize the nasal mucosa. We could
therefore speculate that, perhaps to evade the effects of Lpn2,
N. meningitidis evolved mechanisms to escape the strict
dependence on enterobactin for iron acquisition, by using of
alternative and/or modified siderophores or improving the
removal of iron from various human proteins such as
lactoferrin, transferrin, and hemoglobin.38
In conclusion, we reported here for the first time evidence
that fHbp of N. meningitidis and its counterpart in N. gonorrheae
can bind enterobactin in vitro. The ultimate goal of this study is
to explore new aspects of the fHbp functionality and contribute
to the identification of new targets for drug design.
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